Tracing A Congressional Research Service In Focus brief reviews the three gene therapies FDA approved since 2023 for sickle cell disease, thalassemia, and hemophilia A, and suggests Congress look at long-term risk monitoring and sponsor reporting.×Refreshed just now
Cyber3 days
Vertical
- All verticals
- Space
- Energy
- Quantum
- Robotics
- Cybersecurity
- Biotechnology
- Defense Tech
- Artificial Intelligence
In the News
One card per story, every outlet that covered it22h agoYahooBill Cassidy says Trump’s FDA pick faces uncertain committee voteSenate HELP Chair Bill Cassidy says he still has questions about FDA commissioner nominee Heidi Overton, leaving the outcome of Wednesday's committee vote uncertain.1 outlet9 linked 4d agoLos Angeles TimesFor peptide enthusiasts, a new HHS policy means party timeHHS's enforcement discretion policy lets pharmacies compound six unapproved peptides ahead of a final FDA rule, which critics say expands access without adequate safety or efficacy evidence.1 outletBiotech5 linked
On the Hill
Congress, the White House and agencies3Ahead
Monday, Jan 11
Recent
Friday, Oct 25
Wednesday, Nov 11
3d agoAgencyHealth and Human Services DepartmentFDA announced a draft guidance giving sponsors recommendations for early-phase IND protocols for solid tumor drugs and biologics, with comments due January 11, 2027.BiotechDetails5 linked
Nothing from this branch in view.
Times ET
Contracts
Solicitations, SBIR topics, grants and awards1GrantNational Institutes of HealthOct 20NIH seeks applications for consortium Translational Centers using Microphysiological Systems for Infectious Diseases (RFA-AI-28-012), with a $7M ceiling.$7M ceilingCloses in 75 daysRFA-AI-28-012BiotechLifecycle14 linked